



Express Mail No.: EV 841 454 793 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ternansky et al.

Confirmation No.: 8174

Application No.: 10/722,843

Group Art Unit: 1654

Filed: November 25, 2003

Examiner: Cordero Garcia, Marcela M.

For: PEPTIDES WHICH TARGET TUMOR AND
ENDOTHELIAL CELLS, COMPOSITIONS AND
USES THEREOF

Attorney Docket No.: 9715-024-999
(formerly: 34433/US/4/AMP/SKS)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A01-A22, B01 and C01-C112 listed on the attached form entitled "List of References Cited by Applicant."

Copies of references B01 and C01-C112 are submitted herewith. Copies of references A01-A22 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(4), Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.


Respectfully submitted,

Date: August 11, 2006

Adriane M. Antler 52,605
Adriane M. Antler (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosure



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

9715-024-999

APPLICATION NO.

10/722,843

APPLICANT

Ternansky et al.

FILING DATE

November 25, 2003

ART UNIT

1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	3,845,770	11/05/74	Theeuwes et al.	
	A02	3,916,899	11/04/75	Theeuwes et al.	
	A03	4,440,788	04/03/84	Terayama et al.	
	A04	4,683,202	07/28/87	Mullis	
	A05	4,765,539	08/23/88	Noakes et al.	
	A06	5,112,598	05/12/92	Biesalski	
	A07	5,443,816	08/22/95	Zamora et al.	
	A08	5,556,611	09/17/96	Biesalski	
	A09	5,561,220	10/01/96	Dean et al.	
	A10	5,567,408	10/22/96	Zamora	
	A11	5,618,513	04/08/97	Srinivasan	
	A12	5,627,286	05/16/97	Ramalingam et al.	
	A13	5,639,725	06/17/97	O'Reilly et al.	
	A14	5,698,155	12/16/97	Grosswald et al.	
	A15	5,950,619	09/14/99	van der Linden et al.	
	A16	5,954,047	09/21/99	Armer et al.	
	A17	5,970,974	10/26/99	van der Linden et al.	
	A18	5,994,309	07/25/97	Mazar et al.	
	A19	6,001,965	12/14/99	Livant	
	A20	6,225,284	05/01/01	Albert et al.	
	A21	US 2002/0151501	10/17/02	Bowers et al.	
	A22	US 2004/0162239	08/19/04	Ternansky et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	WO 98/30538	07/16/98	Kaneka Corporation		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9715-024-999	APPLICATION NO. 10/722,843
	APPLICANT Ternansky et al.	
	FILING DATE November 25, 2003	ART UNIT 1654

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	ABOAGYE et al., "Use of positron emission tomography in anticancer drug development," Invest. New Drugs 2003, 21(2):169-181.	
	C02	ADELMAN et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," DNA 1983, 2:183-193.	
	C03	AKIYAMA et al., "Fibronectin and integrins in invasion and metastasis," Cancer Metastasis Rev. 1995, 14(3):173-189.	
	C04	ALDERMAN, "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," Int. J. Pharm. Tech. & Prod. Mfr., 1984, 5(3) 1-9.	
	C05	ALMQUIST et al., "Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme," J. Med. Chem., 1980, 23: 1392-1398.	
	C06	BALDARI et al., "A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in Saccharomyces cerevisiae," EMBO J., 1987, 6: 229-234.	
	C07	BAMBA et al., "Release Mechanisms in Gelforming Sustained Release Preparations," Int. J. Pharm., 1979, 2, 307	
	C08	BEAUCAGE et al., "Deoxynucleoside Phosphoramidites-New Class of Key Intermediates for Deoxypolynucleotide Synthesis," Tetrahedron Lett., 1981, 22:1859.	
	C09	BENJAMIN et al., "Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal," J. Clin. Invest., 1999, 103:159-165.	
	C10	BLOOD et al., "Tumor interactions with the vasculature: angiogenesis and tumor metastasis," Biochem. Biophys. Acta., 1990, 1032: 89-118.	
	C11	BOKEL, "Integrins in development: moving on, responding to, and sticking to the extracellular matrix," Dev. Cell," 2002, 3(3):311-321.	
	C12	BORGSTROM et al., "Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo," Prostate, 1998, 35:1-10.	
	C13	BORNSTEIN et al., "Matricellular proteins: extracellular modulators of cell function," Curr. Opin. Cell Biol. 2002, 14(5):608-616.	
	C14	BROOKS et al. "Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity," Cell, 1998, 92: 391-400.	
	C15	BRUCHEZ et al., "Semiconductor Nanocrystals as Fluorescent Biological Labels," Science, 1998, 281: 2013-2016.	
	C16	CHAMBERS et al., "Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase," Canc. Res., 1995, 55:1578-1585.	
	C17	CHAN et al., "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection," Science, 1998, 281: 2016-2018.	
	C18	CHOREV et al., "Partially modified retro-inverso-enkephalinamides: topochemical long-acting analogs in vitro and in vivo," Science, 1979, 204: 1210-1212.	
	C19	COOPER et al., "The role of alpha(v)beta(3) in prostate cancer progression," Neoplasia 2002, 4(3): 191-194.	
	C20	CROWLEY et al., "Prevention of Metastasis by Inhibition of the Urokinase Receptor," Proc. Natl. Acad. Sci. USA, 1993, 90: 5021-5025.	
	C21	DAMIANO, "Integrins as novel drug targets for overcoming innate drug resistance," Curr. Cancer Drug Targets 2002, 2(1):37-43.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9715-024-999	10/722,843
	APPLICANT Ternansky et al.	
	FILING DATE	ART UNIT
	November 25, 2003	1654

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C22	DURING et al., "Controlled Release of Dopamine from Polymeric Brain Implant: In Vivo Characterization," Ann. Neurol., 1989, 25:351.	
	C23	EDGE et al., "Total synthesis of a human leukocyte interferon gene," Nature 1981, 292:756.	
	C24	FELDING-HABERMANN, "Integrin activation controls metastasis in human breast cancer," Proc. Natl. Acad. Sci. USA 2001, 98(4):1853-1858.	
	C25	FELDING-HABERMANN, "Integrin adhesion receptors in tumor metastasis," Clin. Exp. Metastasis 2003, 20(3): 203-213.	
	C26	FOLKMAN, "Angiogenesis inhibitors generated by tumors," Mol. Med., 1995, 1(2): 120-122.	
	C27	FOLKMAN, "Anti-angiogenesis: new concept for therapy of solid tumors," Ann. Surg., 1972, 175: 409-416.	
	C28	FOLKMAN, "The influence of angiogenesis research on management of patients with breast cancer," Breast Cancer Res. Treat., 1995, 36(2): 109-118.	
	C29	GEIGER et al., "Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk," Nat. Rev. Mol. Cell Biol. 2001, 2(11):793-805.	
	C30	GIANNIS et al., "Peptidomimetics in Drug Design," Adv. in Drug Res., 1997, 29: 1-78.	
	C31	GLASER et al., "Applications of positron-emitting halogens in PET oncology," Int. J. Oncol. 2003, 22(2):253-267.	
	C32	GLUZMAN, "SV40-transformed simian cells support the replication of early SV40 mutants," Cell, 1981, 23:175-182.	
	C33	GOODSON, Medical Applications of Controlled Release, Vol. 2, Chapt. 6, 115-138 (1984).	
	C34	GORELIK et al., "Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity," J. Nat'l. Canc. Inst. 1980, 65:1257-1264.	
	C35	GORELIK et al., "Host's immune state and kinetics of local tumor growth control--progression of postoperative lung metastasis," Rec. Results Canc. Res. 1980, 75:20-28.	
	C36	HANAHAN et al., "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis," Cell 1996, 86(3): 353-364.	
	C37	HERSCHMAN, "Molecular Imaging: Looking at Problems, Seeing Solutions," Science 2003, 302, (5645): 605-608.	
	C38	HILGARD et al., "Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL)," Br. J. Cancer 1977, 35:78-86.	
	C39	HOLLADAY et al., "Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres," Tetrahedron Lett. 1983, 24:4401.	
	C40	HOOD et al., "Role of integrins in cell invasion and migration," Nat. Rev. Cancer 2002, 2(2): 91-100	
	C41	HOWARD et al., "Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficit," J. Neurosurg. 1989, 71:105.	
	C42	HRUBY, "Conformational and topographical considerations in the design of biologically active peptides," Biopolymers 1993, 33: 1073-1082.	
	C43	HRUBY, "Conformational Restrictions of Biologically Active Peptides Via amino Acid Side Chain Groups," Life Sci. 1982, 4:189-199.	
	C44	ISAKOV et al., "An immune response against the alloantigens of the 3LL Lewis lung carcinoma prevents the growth of lung metastases, but not of local allografts," Invasion Metas. 1982, 2:12-32.	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9715-024-999	APPLICATION NO. 10/722,843
	APPLICANT Ternansky et al.	
	FILING DATE November 25, 2003	ART UNIT 1654

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C45	JAY, "Chemical synthesis of a biologically active gene for human immune interferon-gamma. Prospect for site-specific mutagenesis and structure- function studies," J. Biol. Chem. 1984, 259:6311.	
	C46	JENNINGS-WHITE et al., "Synthesis of Ketomethylene Analogs of Dipeptides," Tetrahedron Letters, 1982, 23:2533.	
	C47	KAUFMAN et al., "Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian," EMBO J. 1987, 6:187-195.	
	C48	KEMPERMAN et al., "The role of integrins and integrin activation in liver metastasis," Invasion Metastasis 1994-95, 14(1-6):98-108.	
	C49	KERR et al., "The alpha v integrin antagonists as novel anticancer agents: an update," Expert Opin. Investig. Drugs 2002, 11(12):1765-1774.	
	C50	KIM et al., "Regulation of Angiogenesis in Vivo by Ligation of Integrin 5B1 with the Central Cell-Binding Domain of Fibronectin," Am. J. Pathol. 2000, 156(4):1345-1362.	
	C51	KLEINMAN et al., "Basement membrane complexes with biological activity," Biochemistry 1986, 25: 312-318.	
	C52	KUMAR, "Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis," Curr. Drug. Targets 2003, 4(2):123-131.	
	C53	KURJAN et al. "Structure of a yeast pheromone gene (MF alpha): a putative alpha-factor precursor contains four tandem copies of mature alpha-factor," Cell 1982, 30:933-943	
	C54	LABAT-ROBERT, "Fibronectin in Malignancy," Semin. Cancer Biol. 2002, 12(3):187-195.	
	C55	LANGER, "New methods of drug delivery," Science 1990, 249:1527-1533.	
	C56	LANGER et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," J. Macromol. Sci. Rev. Macromol Chem. 1983, 23:61.	
	C57	LEVY et al., "Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate," Science 1985 228: 190.	
	C58	LI et al., "Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates," Biomacromolecules 2003, 4:1055-1067.	
	C59	LIU et al., "Antiangiogenic therapy," Semin. Oncol. 2002, 29 (3 Suppl. 11): 96-103.	
	C60	LOHR et al., "Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas," Pancreas 1996, 12(3):248-259.	
	C61	LUCKOW et al., "High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression vectors," Virology 1989, 170:31-39.	
	C62	MALAVE et al., "Influence of inoculation site on development of the Lewis lung carcinoma and suppressor cell activity in syngeneic mice," J. Nat'l. Canc. Inst. 1979, 62:83-88.	
	C63	MATTEUCCI et al., "Synthesis of Deoxyoligonucleodites on a Polymer Support," J. Am. Chem. Soc. 1981, 103:3185.	
	C64	MAXAM et al., "Sequencing end-labeled DNA with base-specific chemical cleavages," Meth. Enzymol. 1980, 65:499-560.	
	C65	MERAJVER et al., "Cooper Depletion as and Anti-Angiogenic Strategy in HER2-neu Transgenic," Proceedings of Special AACR Conference on Angiogenesis and Cancer 1998, Abstract #B-11, January 22-24.	
	C66	MERRIFIELD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Terapeptide," J. Amer. Chem. Soc. 1963, 85: 2149-2154.	
	C67	MESSING et al., "A system for shotgun DNA sequencing," Nucleic Acids Res. 1981, 9:309.	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9715-024-999	APPLICATION NO. 10/722,843
	APPLICANT Ternansky et al.	
	FILING DATE November 25, 2003	ART UNIT 1654

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C68	METZNER et al., "Evidence of the involvement of phosphatidylinositol 3-kinase in the migration, actin stress fiber formation, and alpha v beta 3-integrin- mediated adherence of human melanoma cells," J. Invest. Dermatol. 1996, 107(4): 597-602.	
	C69	MILLAUER et al., "Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo," Cancer Res. 1996, 56: 1615-1620.	
	C70	MIN et al., "Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice," Cancer Res. 1996, 56: 2428-2433.	
	C71	MOORE et al., "Design and pharmacology of peptide mimetics," Adv. in Pharmacol. 1995, 33: 91-141.	
	C72	NAMBIAR et al., "Total synthesis and cloning of a gene coding for the ribonuclease S protein," Science 1984, 223:1299.	
	C73	NGUYEN et al., "Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane," Microvascular Res. 1994, 47:31 40.	
	C74	NIP et al., "The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis," Cancer Metastasis Rev. 1995, 14(3): 241-252.	
	C75	O'BRIEN et al., "Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation," Exp. Cell Res. 1996, 224(1): 208-213.	
	C76	O'REILLY et al. "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, 1994, 79:315-328.	
	C77	O'REILLY et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell 1997, 88:277-285.	
	C78	ODEDRA et al., "Low molecular weight angiogenesis factors," Pharmac. Ther. 1991, 49:111-124.	
	C79	OLSON et al., "Concepts and progress in the development of peptide mimetics," J. Med. Chem. 1993, 36: 3039.	
	C80	PARISH et al., "A basement-membrane permeability assay which correlates with the metastatic potential of tumor cells," Int. J. Cancer 1992, 52: 378-383.	
	C81	PASSANITI et al., A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992 67:519-528.	
	C82	PECHEUR et al., "Integrin alpha v beta 3 expression confers on tumor cells a greater propensity to metastasize to bone," FASEB J. 2002, 16(10): 1266-1268.	
	C83	PLATTEN et al., "Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression," Biochem. Biophys. Commun. 2000, 268(2): 607-611.	
	C84	RABB et al., "Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney," Am. J. Nephrol. 1996, 16(5):402-408.	
	C85	RABBANI et al., "Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)," Int. J. Cancer 1995, 63: 840-845.	
	C86	RALEIGH et al., "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," British J. Cancer, 1999, 80 Suppl. 2, 96.	
	C87	RUOSLAHTI, "Fibronectin and its alpha 5 beta 1 integrin receptor in malignancy," Invasion Metastasis 1994; 14(1-6): 87-97.	
	C88	RUST et al., "The Promise of Integrins as Effective Targets for Anticancer Agents," J. Biomed. Biotechnol. 2002, 2(3): 124-130.	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9715-024-999	10/722,843
	APPLICANT Ternansky et al.	
	FILING DATE	ART UNIT
	November 25, 2003	1654

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C89	SANGER, "DNA sequencing with chain-terminating inhibitors," Proc. Natl. Acad. Sci. USA 1977, 74:5463-5467.	
	C90	SAUDEK et al., "A preliminary trial of the programmable implantable medication system for insulin delivery," N. Engl. J Med. 1989 321:574-579.	
	C91	SCHNAPER et al., "Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways," J. Cell. Physiol. 1995, 165: 107-118.	
	C92	SCHULTZ et al., "Expression and Secretion in Yeast of a 400-kDA Envelope Glycoprotein Derived from Epstein-Barr Virus," Gene 1987, 54:113-123.	
	C93	SEFTON, "Implantable pumps," CRC Crit. Ref. Biomed. Eng. 1987, 14:201-240.	
	C94	SHOCKLEY et al., "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," Ann. N.Y. Acad. Sci., 1991, 617:367-382.	
	C95	SMITH et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Mol. Cell Biol., 1983, 3:2156-2165.	
	C96	SPATOLA, "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins," B. Weinstein, (eds.), Marcel Dekker, New York, 1983, pp. 267-357.	
	C97	SPATOLA et al., "Structure-Activity Relationships of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates," Life Sci., 1986, 38:1243-1249.	
	C98	STOELTZING et al., "Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice," Int. J. Cancer 2003, 104(4):496-503.	
	C99	STUPACK et al., "Get a ligand, get a life: integrins, signaling and cell survival," J. Cell Sci. 2002, 115: 3729-38.	
	C100	TALMADGE et al., "Enhanced Metastatic Potential of Tumor Cells Harvested from Spontaneous Metastases of Heterogeneous Murine Tumors J. Nat'l. Canc. Inst. 1982, 69:975-980.	
	C101	TANI et al., "Expression level of integrin alpha 5 on tumor cells affects the rate of metastasis to the kidney," Br. J. Cancer 2003, 88(2): 327-333.	
	C102	THAKUR et al., "Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs," J. Lab. Clin. Med. 1977, 89:217-228.	
	C103	TREAT et al., in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez Berestein and Fidler (eds.), Liss, New York, pp.353-365 (1989).	
	C104	TUCKER, "Inhibitors of integrins," Curr. Opin. Pharmacol. 2002, 2(4): 394-402.	
	C105	VAN DE WIELE et al., "Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging," Eur. J. Nucl. Med. Mol. Imaging 2002, 29(5): 699-709.	
	C106	VARNER et al., "Tumor angiogenesis and the role of vascular cell integrin alphavbeta3," Import Adv. Oncol. 1996, 69-87.	
	C107	VERMA et al., "Osmotically Controlled Oral Drug Delivery," Drug Dev. Ind. Pharm., 2000, 26:695-708.	
	C108	VERSCHOYLE et al., "Pharmacokinetics of Isotretinoin (ISO) in Rats following Oral Dosing or Aerosol Inhalation," Br. J. Cancer 1999, 80 Suppl. 2: 96.	
	C109	VOLPERT et al., "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," J. Clin. Invest. 1996, 98: 671-679.	
	C110	WILEY et al., "Peptidomimetics Derived from Natural Products," Med. Res. Rev. 1993, 13: 327-384.	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9715-024-999	APPLICATION NO. 10/722,843
	APPLICANT Ternansky et al.	
	FILING DATE November 25, 2003	ART UNIT 1654

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C111	XING et al., "Overexpression of Urokinase Receptor in Breast Int. J. Cancer 1996, 67: 423-429.	
	C112	ZOLLER et al., "Oligonucleotide-Directed Mutagenesis using M13-Derived Vectors: an Efficient and General Procedure for the Production of Point Mutations in any Fragment of DNA," Nucleic Acids Res. 1982, 10:6487-6500.	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	